TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06640205

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pulpotomy
Description: Removal of coronal pulp tissue and then placing pulpotomy agent

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pulpotomy
Description: Removal of coronal pulp tissue and then placing pulpotomy agent

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pulpotomy
Description: Removal of coronal pulp tissue and then placing pulpotomy agent
Study: NCT06639984

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Psyllium (0.7 g/year of age per day)
Description: Psyllium (0.7 g/year of age per day) (Konsyl Pharmaceuticals, Easton, MD)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Psyllium (0.5 g/year of age per day)
Description: Psyllium (0.5 g/year of age per day) (Konsyl Pharmaceuticals, Easton, MD)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (0.7 g/year of age glucose) (Staleydex 333; Tate \&amp; Lyle, Staley, London, UK)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: fructans
Description: Daily dose 0.5 g/kg up to 19 grams, Orafti Synergy1

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: fructans
Description: Daily dose 0.5 g/kg up to 19 grams, Orafti Synergy1

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: fructans
Description: Daily dose 0.5 g/kg up to 19 grams, Orafti Synergy1
Study: NCT06638554

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active Choice
Description: The participant will be send a letter inviting them to complete a SDM visit either in-person or via telehealth.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active Choice
Description: The participant will be send a letter inviting them to complete a SDM visit either in-person or via telehealth.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telehealth Only
Description: The participant will be send a letter inviting them to complete a SDM visit via telehealth only.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telehealth Only
Description: The participant will be send a letter inviting them to complete a SDM visit via telehealth only.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low Touch Strategy
Description: Patient will be sent asynchronous text messaging reminders encouraging SDM for LCS using framed messaging.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low Touch Strategy
Description: Patient will be sent asynchronous text messaging reminders encouraging SDM for LCS using framed messaging.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Touch Strategy
Description: Patient will be sent asynchronous text messaging reminders encouraging SDM for LCS using framed messaging in combination with synchronous telephone-based digital care coordination.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Touch Strategy
Description: Patient will be sent asynchronous text messaging reminders encouraging SDM for LCS using framed messaging in combination with synchronous telephone-based digital care coordination.
Study: NCT06641960

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probiotics
Description: In this group, the patients will undergo orthodontic treatment with metallic appliances and receive oral hygiene instruction with probiotic lozenges.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional treatment
Description: In this group, the patients will undergo orthodontic treatment with metallic appliances and receive oral hygiene instruction without probiotic lozenges.
Study: NCT06638827

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic Sympathectomy
Description: Bilateral thoracoscopic sympathectomy will be performed with general anesthesia, using single lung ventilation and monopolar cautery for transection of the sympathetic chain.~Persons with PFH who underwent the BTS were classified into three groups, depending the level of transaction of sympathetic chain:~1. transection at the level from the second to the forth thoracic sympathetic ganglion (T2- T4);~2. transection at the level from the third to the forth thoracic sympathetic ganglion (T3-T4)~3. transection at the level from the second to the third thoracic sympathetic ganglion (T2-T3)..
Study: NCT06637696

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blood Culture Bundle
Description: In this pre and post intervention study investigators aimed to evaluate the impact of a blood culture bundles on the incidence of blood culture contamination rates in NICU.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Blood Culture Bundle
Description: In this pre and post intervention study investigators aimed to evaluate the impact of a blood culture bundles on the incidence of blood culture contamination rates in NICU.
Study: NCT05818254

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HOP-STEP (Healthy Outcomes in Pregnancy with SLE Through Education of Providers) Intervention
Description: The HOP-STEP Intervention is simple with 3-steps: (1) ascertain and document current pregnancy intention and contraceptive use, (2) patient and provider collaboratively arrive at her optimal contraceptive and/or pregnancy plan using a Decision Guide directed conversation, and (3) create a warm handoff with a patient-specific SLE risk assessment and guideline-aligned recommendations.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Routine Care
Description: Providers will continue to provide reproductive healthcare in their current manner.
Study: NCT06638047

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: robotic-assisted TKA
Description: Robotic-assisted TKA means that TKA surgery is operated with the guidance of robotic system.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CI-TKA
Description: TKA operated with conventional instruments
Study: NCT06645379

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Platelet-Rich Plasma (PRP) Injections
Description: Transvaginal or laparoscopic injection for ovarian diseases (Premature ovarian insufficiency and Poor ovarian response). Intrauterine perfusion or sub-endometrium injection for uterine diseases (intrauterine adhesion, thin endometrium, and repeated implantation failure)
Study: NCT05467826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir/Velpatasvir + Ribavirin
Description: Sofosbuvir 400mg/velpatasvir 100mg + ribavirin 1000mg/1200mg for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir/Velpatasvir/Voxilaprevir
Description: Sofosbuvir 400mg/velpatasvir 100mg/voxilaprevir 100mg for 12 weeks
Study: NCT04174573

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GTO
Description: 1. Forward direction activity: Balance activity in forward direction on wooden balance board (5 reps X 3 sets X 2 days in a week, for 6 weeks)~2. Backward direction activity: Balance activity in backward direction on wooden balance board (5 reps X 3 sets X 2 days in a week, for 6 weeks)~3. Sideways direction activity: Balance activity in sideways direction on wooden balance board (5 reps X 3 sets X 2 days in a week, for 6 weeks)
Study: NCT04410042

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% sodium chloride
Description: Given IV
Study: NCT06644001

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bacillus coagulans GBI-30,6086 (BC GBI-30)
Description: 2g powder/sachet, consists of bacillus coagulans at a dose of 1x10\^9 CFU, taken once daily before a meal.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2g powder/sachet, consists of maltodextrin only, taken once daily before a meal.
Study: NCT06643819

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sacubitril/valsatran(dose maintenance)
Description: During the 4 weeks of Placebo Run-in Period(Single blind), all participants are treated 1 placebo of CKD-202A(Sacubitril∙Valsartan) 100mg and 1 placebo of D763(Valsartan 80 mg) each, total of 2 oral doses once a day.~After Placebo Run-in Period, During the 4 weeks out of 10 weeks of Treatment Period(Double blind), All TEST1 pariticipants are treated 1 CKD-202A (Sacubitril∙Valsartan) 100 mg and 1 placebo of D763(Valsartan 80 mg) each, total of 2 oral doses once a day.~After 4 weeks of Treatment Period, During the 6 weeks out of 10 weeks of Treatment Period(Double blind), All TEST1 pariticipants are treateed 1 CKD-202A (Sacubitril∙Valsartan) 100 mg, 1 placebo of CKD-202A(Sacubitril∙Valsartan) 200mg, 1 placebo of D764(Valsartan 160 mg) each, and a total of 3 oral doses once a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sacubitril/valsartan(dose increasing)
Description: During the 4 weeks of Placebo Run-in Period(Single blind), all participants are treated 1 placebo of CKD-202A(Sacubitril∙Valsartan) 100mg and 1 placebo of D763(Valsartan 80 mg) each, total of 2 oral doses once a day.~After Placebo Run-in Period, During the 4 weeks out of 10 weeks of Treatment Period(Double blind), All TEST2 pariticipants are treated 1 CKD-202A (Sacubitril∙Valsartan) 100 mg and 1 placebo of D763(Valsartan 80 mg) each, total of 2 oral doses once a day.~After 4 weeks of Treatment Period, During the 6 weeks out of 10 weeks of Treatment Period(Double blind), All TEST1 pariticipants are treateed 1 placebo of CKD-202A (Sacubitril∙Valsartan) 100 mg, 1 CKD-202A(Sacubitril∙Valsartan) 200mg, 1 placebo of D764(Valsartan 160 mg) each, and a total of 3 oral doses once a day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan
Description: During the 4 weeks of Placebo Run-in Period(Single blind), all participants are treated 1 placebo of CKD-202A(Sacubitril∙Valsartan) 100mg and 1 placebo of D763(Valsartan 80 mg) each, total of 2 oral doses once a day. After Placebo Run-in Period, During the 4 weeks out of 10 weeks of Treatment Period(Double blind), All TEST2 pariticipants are treated 1 placebo of CKD-202A (Sacubitril∙Valsartan) 100 mg and 1 D763(Valsartan 80 mg) each, total of 2 oral doses once a day. After 4 weeks of Treatment Period, During the 6 weeks out of 10 weeks of Treatment Period(Double blind), All TEST1 pariticipants are treateed 1 placebo of CKD-202A (Sacubitril∙Valsartan) 100 mg, 1 placebo of CKD-202A(Sacubitril∙Valsartan) 200mg, 1 D764(Valsartan 160 mg) each, and a total of 3 oral doses once a day.
Study: NCT04821310

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Full dose Pantoprazole plus matching placebo
Description: Full healing dose of pantoprazole plus matching placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Half Dose Pantoprazole plus matching placebo
Description: Half healing dose of pantoprazole plus matching placebo
Study: NCT04886856

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful Moms
Description: Twelve 75 minutes weekly group sessions involving gentle yoga practices designed for pregnant women, led by experienced yoga teachers.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Prenatal Education
Description: Twelve 75 minutes weekly group sessions involving prenatal education (for example, what to expect during your pregnancy, during labor and delivery, and after the delivery of your child).
Study: NCT06571331

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: De-Stress & Snooze Gummies-U001
Description: Two gummies daily in sequence 30-45 minutes before bed for 60 days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: De-Stress & Snooze Gummies-I001
Description: Two gummies daily in sequence 30-45 minutes before bed for 60 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Gummies 002
Description: Two gummies daily in sequence 30-45 minutes before bed for 60 days
Study: NCT04174573

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GT-tDCS
Description: 1. Group therapy~   1. Forward direction activity: Balance activity in forward direction on wooden balance board (5 reps X 3 sets X 2 days in a week, for 6 weeks)~  2. Backward direction activity: Balance activity in backward direction on wooden balance board (5 reps X 3 sets X 2 days in a week, for 6 weeks)~  3. Sideways direction activity: Balance activity in sideways direction on wooden balance board (5 reps X 3 sets X 2 days in a week, for 6 weeks)~2. tDCS Left anodal and right cathodal tDCS : Anode- F3, Cathode- Right Supra orbital area, Intensity- 2mA, Duration- 30 minutes, once in a week for 6 weeks
Study: NCT05598034

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Left DLPFC tDCS
Description: This intervention involves placing non-invasive scalp-electrodes over the left DLPFC brain region to deliver a mild, tolerable electric current.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Left DLPFC tDCS
Description: This intervention involves placing non-invasive scalp-electrodes over the left DLPFC brain region to deliver a mild, tolerable electric current.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Right DLPFC tDCS
Description: This intervention involves placing non-invasive scalp-electrodes over the right DLPFC brain region to deliver a mild, tolerable electric current.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Right DLPFC tDCS
Description: This intervention involves placing non-invasive scalp-electrodes over the right DLPFC brain region to deliver a mild, tolerable electric current.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive task
Description: Participants will be asked to perform a 2-back working memory mental task alongside administered tDCS

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive task
Description: Participants will be asked to perform a 2-back working memory mental task alongside administered tDCS
Study: NCT05709782

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spine Radiosurgery
Description: scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spine Radiosurgery
Description: scan

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance imaging
Description: scan

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance imaging
Description: scan

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: MR-LINAC
Description: scan
Study: NCT05725902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etavopivat
Description: The study intervention is etavopivat (400 mg), administered orally and once daily (QD)
Study: NCT04954859

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bepirovirsen
Description: No study drug will be administered in this study. Eligible participants who received prior treatment with bepirovirsen in the parent studies will be included.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bepirovirsen
Description: No study drug will be administered in this study. Eligible participants who received prior treatment with bepirovirsen in the parent studies will be included.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bepirovirsen
Description: No study drug will be administered in this study. Eligible participants who received prior treatment with bepirovirsen in the parent studies will be included.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: No study drug will be administered in this study. Eligible participants who received prior treatment with placebo in the parent studies (209668, 202009, and 219288) will be included to maintain the blind in the still ongoing parent studies.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: No study drug will be administered in this study. Eligible participants who received prior treatment with placebo in the parent studies (209668, 202009, and 219288) will be included to maintain the blind in the still ongoing parent studies.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: No study drug will be administered in this study. Eligible participants who received prior treatment with placebo in the parent studies (209668, 202009, and 219288) will be included to maintain the blind in the still ongoing parent studies.
Study: NCT05135273

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pfs230D1-EPA/Matrix-M Vaccine
Description: Each single-use vial of Pfs230D1M-EPA contains 160 µg/mL of conjugated Pfs230D1M and 124 µg/mL or 143 µg/mL of conjugated EPA in 4 mM phosphate-buffered saline (PBS), in a volume of 0.5 mL. Each vial of Matrix-M1 contains saponin content of 0.375 mg/mL in PBS, at a pH of 7.2, in a final volume of 0.75 mL. Components will be combined in volumes defined in the protocol at point of use.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pfs230D1-EPA/Matrix-M Vaccine
Description: Each single-use vial of Pfs230D1M-EPA contains 160 µg/mL of conjugated Pfs230D1M and 124 µg/mL or 143 µg/mL of conjugated EPA in 4 mM phosphate-buffered saline (PBS), in a volume of 0.5 mL. Each vial of Matrix-M1 contains saponin content of 0.375 mg/mL in PBS, at a pH of 7.2, in a final volume of 0.75 mL. Components will be combined in volumes defined in the protocol at point of use.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pfs230D1-EPA/Matrix-M Vaccine
Description: Each single-use vial of Pfs230D1M-EPA contains 160 µg/mL of conjugated Pfs230D1M and 124 µg/mL or 143 µg/mL of conjugated EPA in 4 mM phosphate-buffered saline (PBS), in a volume of 0.5 mL. Each vial of Matrix-M1 contains saponin content of 0.375 mg/mL in PBS, at a pH of 7.2, in a final volume of 0.75 mL. Components will be combined in volumes defined in the protocol at point of use.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pfs230D1-EPA/Matrix-M Vaccine
Description: Each single-use vial of Pfs230D1M-EPA contains 160 µg/mL of conjugated Pfs230D1M and 124 µg/mL or 143 µg/mL of conjugated EPA in 4 mM phosphate-buffered saline (PBS), in a volume of 0.5 mL. Each vial of Matrix-M1 contains saponin content of 0.375 mg/mL in PBS, at a pH of 7.2, in a final volume of 0.75 mL. Components will be combined in volumes defined in the protocol at point of use.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pfs230D1-EPA/Matrix-M Vaccine
Description: Each single-use vial of Pfs230D1M-EPA contains 160 µg/mL of conjugated Pfs230D1M and 124 µg/mL or 143 µg/mL of conjugated EPA in 4 mM phosphate-buffered saline (PBS), in a volume of 0.5 mL. Each vial of Matrix-M1 contains saponin content of 0.375 mg/mL in PBS, at a pH of 7.2, in a final volume of 0.75 mL. Components will be combined in volumes defined in the protocol at point of use.
Study: NCT06634771

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 10 Hz transcranial alternating current stimulation (tACS)
Description: 10 Hz bi-frontal tACS: Alternating current stimulation is delivered by an XCSITE 100 device (Pulvinar Neuro, Chapel Hill, NC), through three conductive carbon-rubber electrodes. Electrodes are placed over the apex of the head (Cz) and the prefrontal cortex bilaterally (F3 and F4). Stimulation is delivered during the second half of the HABIT Test session. Stimulation parameters: 2mA peak-to-peak 10Hz sine-wave flanked by 10 second linear envelope ramps in and out for a total duration of 30 min and 20 seconds.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham transcranial alternating current stimulation (tACS)
Description: Sham tACS: The procedure for sham stimulation will be identical, but it will last for 2 minutes instead of 30 minutes.
Study: NCT06630130

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab deruxtecan
Description: * Neoadjuvant; Trastuzumab Deruxtecan(T-DXd) 5.4mg/kg IV on D1, Q3W for 3 cycles~* Adjuvant; Trastuzumab Deruxtecan(T-DXd) 5.4mg/kg IV on D1, Q3W 16 cycles (up to 12 months)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab deruxtecan
Description: * Neoadjuvant; Trastuzumab Deruxtecan(T-DXd) 5.4mg/kg IV on D1, Q3W for 3 cycles~* Adjuvant; Trastuzumab Deruxtecan(T-DXd) 5.4mg/kg IV on D1, Q3W 16 cycles (up to 12 months)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: * Neoadjuvant; Capecitabine 1000mg/m2 PO BID on D1-D14, Q3W for 3 cycles~* Adjuvant; Capecitabine 1000mg/m2 PO BID on D1-D14, Q3W for 4 cycles (up to 3 months)
Study: NCT05135273

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pfs230D1-EPA/Matrix-M Vaccine
Description: Each single-use vial of Pfs230D1M-EPA contains 160 µg/mL of conjugated Pfs230D1M and 124 µg/mL or 143 µg/mL of conjugated EPA in 4 mM phosphate-buffered saline (PBS), in a volume of 0.5 mL. Each vial of Matrix-M1 contains saponin content of 0.375 mg/mL in PBS, at a pH of 7.2, in a final volume of 0.75 mL. Components will be combined in volumes defined in the protocol at point of use.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Verorab Rabies Vaccine
Description: Verorab Rabies Vaccine is a purified inactivated rabies vaccine (Wistar rabies PM/WI 38 1503-3M strain) prepared on Vero cells. It is supplied as a powder and solvent for suspension for injection in a prefilled syringe. Before reconstitution, the powder is a white and homogeneous pellet. The solvent is a limpid solution.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Verorab Rabies Vaccine
Description: Verorab Rabies Vaccine is a purified inactivated rabies vaccine (Wistar rabies PM/WI 38 1503-3M strain) prepared on Vero cells. It is supplied as a powder and solvent for suspension for injection in a prefilled syringe. Before reconstitution, the powder is a white and homogeneous pellet. The solvent is a limpid solution.
Study: NCT06630130

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: * Neoadjuvant; Capecitabine 1000mg/m2 PO BID on D1-D14, Q3W for 3 cycles~* Adjuvant; Capecitabine 1000mg/m2 PO BID on D1-D14, Q3W for 4 cycles (up to 3 months)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rilvegostomig
Description: (Only Cohort B)~* Neoadjuvant; Rilvegostomig 750mg IV on D1, Q3W for 3 cycles~* Adjuvant; Rilvegostomig 750mg IV on D1, Q3W for 16 cycles (up to 12 months)
Study: NCT06631391

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: umbilical cord blood NK cells
Description: This is a phase I prospective clinical trial, including phase Ia and phase Ib. Phase Ia include 3 dose levels, utilizing a 3+3 design principle, and each dose level will enroll at least 3 subjects. The recommended dose for phase Ia was used in phase Ib. Each patient receives two courses of umbilical cord blood NK cell therapy (a total of 8 infusions of umbilical cord blood NK cells).
Study: NCT06515652

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rosuvastatin, METFORMIN, Sitagliptin, Telmisartan, Cinnamon. garlic, Ginger, Methi dana, Arjun
Description: Comparing allopathic and herbal group of drugs for metabolic syndrome

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rosuvastatin, METFORMIN, Sitagliptin, Telmisartan, Cinnamon. garlic, Ginger, Methi dana, Arjun
Description: Comparing allopathic and herbal group of drugs for metabolic syndrome
Study: NCT06424262

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CI622D
Description: A dexamethasone-eluting Slim Straight electrode

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CI622
Description: A standard Slim Straight electrode